Clinical Trials Browser

Phase 1 × mogamulizumab × 90 days × Clear all

NCT04848064 2026-02-10

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Phase 1 Recruiting

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma